A Randomized, Open-label, Phase I, Crossover Study to Assess the Effect of Food on the Bioavailability of AXL1717, in Patients With Advanced Malignant Tumors

NCT01725555 Phase 1 COMPLETED

This is a prospective, randomized, open-label, Phase I, crossover study to assess the effect of food on the bioavailability of AXL1717 including patients with advanced malignant tumors

Details

Lead sponsor	Axelar AB
Phase	Phase 1
Status	COMPLETED
Enrolment	13
Start date	2012-10
Completion	2013-12

Conditions

• Solid Tumors
• Hematological Malignancies

Interventions

• Fasted treatment: AXL1717
• Fed treatment: AXL1717

Primary outcomes

• Single dose AXL1717 serum pharmacokinetic profile under fasting versus fed condition in each patient — several samples within 24 hours

Countries

Sweden